Ads
related to: sinemet alternatives for diabetes- Learn About T1D Treatment
Discover T1D Treatment for
Appropriate Patients.
- Physician Resources
View Helpful Resources
For Physicians Now.
- How to Screen for T1D
Learn How to Screen
Patients for T1D.
- Learn About Dosing
Read Important Dosing
Information and Resources.
- Learn About T1D Treatment
Search results
Results From The WOW.Com Content Network
Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. [6] It is primarily used to manage the symptoms of Parkinson's disease, but it does not slow down the disease or stop it from getting worse. [6]
SGLT2 inhibitors are used in the treatment of type 2 diabetes. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with type 2 diabetes. [2] [3] As of 2014, several medications of this class had been approved or were under development. [4]
Alpha-glucosidase inhibitors (AGIs) are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates (such as starch and table sugar). They are found in raw plants/herbs such as cinnamon and bacteria (containing the inhibitor acarbose ).
1. Maple syrup. Type: Natural sweetener. Potential benefits: Maple syrup is high in antioxidants and rich in minerals, including calcium, potassium, iron, zinc, and manganese.However, like other ...
Canagliflozin is indicated to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes; to reduce the risk of major heart-related events such as heart attack, stroke, or death in people with type 2 diabetes who have known heart disease; and to reduce the risk of end-stage kidney disease, worsening of kidney function, heart-related death, and being hospitalized for ...
A recent study has shown that people who take SGLT-2 inhibitors for type 2 diabetes management have a 35% lower diabetes risk, overall. A diabetes drug may help prevent dementia, new research ...